Methods for treating disorders involving monocytes

A method of treating a disease involving monocytic activity comprising administering a therapeutically effective amount of an IL-15 antagonist that induces apoptosis of monocytes, wherein the disease is a connective disorder selected from the group consisting of retroperitoneal fibrosis, familial Mediterranean fever, and tumor necrosis factor receptor-associated periodic syndromes.

A method of treating a disease involving monocytic activity comprising administering a therapeutically effective amount of an IL-15 antagonist that induces apoptosis of monocytes, wherein the disease is a neurological disorder selected from the group consisting of stroke, cerebral trauma, Guillain-Barré syndrome/polyradiculitis, chronic inflammatory demyelinating polyneuropathy, and Alzheimer's disease.

A method of treating a disease involving monocytic activity comprising administering a therapeutically effective amount of an IL-15 antagonist that induces apoptosis of monocytes, wherein the disease is a gastrointestinal or hepatic disorder selected from the group consisting of alcoholic hepatitis, hepatitis C, acute pancreatitis, Whipple's disease, chronic active hepatitis, and sclerosing cholangitis.

A method of treating a disease involving monocytic activity comprising administering a therapeutically effective amount of an IL-15 antagonist that induces apoptosis of monocytes, wherein the disease is an allergic disorder selected from the group consisting of chronic urticaria and angioedema.

A method of treating a disease involving monocytic activity comprising administering a therapeutically effective amount of an IL-15 antagonist that induces apoptosis of monocytes, wherein the disease is a hematologic disorder selected from the group consisting of hemophagocytic syndrome and histiocytosis X.

A method of treating a disease involving monocytic activity comprising administering a therapeutically effective amount of an IL-15 antagonist that induces apoptosis of monocytes, wherein the disease is a skin disorder selected from the group consisting of pemphigus vulgaris, linear IgA dermatitis, dermatitis herpetiformis, epidermolysis bullosa acquisita, acne vulgaris and rosacea.

A method of treating a disease involving monocytic activity comprising administering a therapeutically effective amount of an IL-15 antagonist that induces apoptosis of monocytes, wherein the disease is a pulmonary disorder selected from the group consisting of pulmonary silicosis, berylliosis, and asbetosis.

A method of treating a disease involving monocytic activity comprising administering a therapeutically effective amount of an IL-15 antagonist that induces apoptosis of monocytes, wherein the disease is prostatic cancer.

A method of treating a disease involving monocytic activity comprising administering a therapeutically effective amount of an IL-15 antagonist that induces apoptosis of monocytes, wherein the disease is an endocrinological disorder, selected from the group consisting of insulin-dependent diabetes mellitus, vasculititis panniculitis, erythema nodosum, and Behçet's syndrome.

A method of treating a disease involving monocytic activity comprising administering a therapeutically effective amount of an IL-15 antagonist that induces apoptosis of monocytes, wherein the disease is an infectious disorder selected from the group consisting of leishmaniasis and infectious mononucleosis.

A method of treating a disease involving monocytic activity comprising administering a therapeutically effective amount of an IL-15 antagonist that induces apoptosis of monocytes, wherein the disease is a kidney disorder selected from the group consisting of chronic renal failure, acute glomerulonephritis, chronic glomerulonephritis, ANCA-associated nephritides, and nephrosclerosis.

A method of treating a disease involving monocytic activity comprising administering a therapeutically effective amount of an IL-15 antagonist that induces apoptosis of monocytes, wherein the disease is selected from the group consisting of cardiac disorders, circulatory disorders, metabolic disorders, coagulation disorders, bone disorders, and muscle disorders.

A method of treating a disease comprising administering a therapeutically effective amount of an IL-15 antagonist that induces apoptosis of a cell, wherein the cell is selected from the group consisting of T cells, B cells, neutrophils, mast cells, keratinocytes, NK T cells, and NK cells.